Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression

Molecular Medicine Reports

Volumn 11, Issue 3, 2015, Pages 2334-2340

  Huang, Xin ^a   Ma, Jiancang ^a   Xu, Jinkai ^a   Su, Qinghua ^a   Zhao, Jun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Apoptosis; Hepatocellular carcinoma; Notch1; Phosphorylated Akt; Simvastatin

Indexed keywords

BETA ACTIN; NOTCH1 RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE INACTIVATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HEPG2 CELL LINE; LIVER TUMOR; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, NOTCH1; RNA, MESSENGER; SIMVASTATIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84916608545     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2976     Document Type: Article

References (45)

1. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.
2. Tsochatzis E, Meyer T, O'Beirne J and Burroughs AK: Transarterial chemoembolisation is not superior to embolisation alone: The recent European Association for the Study of the Liver (EASL)-European Organisation for Research and Treatment of Cancer (EORTC) guidelines. Eur J Cancer 49: 1509-1510, 2013.
3. Cabibbo G, Rolle E, De Giorgio M, et al: Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. Expert Rev Anticancer Ther 11: 1807-1816, 2011.
4. Parkin DM: Global cancer statistics in the year 2000. Lancet Onco 2: 533-543, 2001.
5. Jakobisiak M and Golab J: Statins can modulate effectiveness of antitumor therapeutic modalities. Med Res Rev 30: 102-135, 2010.
6. Jakobisiak M and Golab J: Potential antitumor effects of statins (Review). Int J Oncol 23: 1055-1069, 2003.
7. Graaf MR, Richel DJ, van Noorden CJ and Guchelaar HJ: Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30: 609-641, 2004.
8. Liao JK and Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118, 2005.
9. Freed-Pastor WA, Mizuno H, Zhao X, et al: Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148: 244-258, 2012.
10. Kochuparambil ST, Al-Husein B, Goc A, Soliman S and Somanath PR: Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther 336: 496-505, 2011.
11. Wang Y, Xu SL, Wu YZ, et al: Simvastatin induces caspase-dependent apoptosis and activates p53 in OCM-1 cells. Exp Eye Res, 2013.
12. Xu J, Liu X, Chen J, et al: Simvastatin enhances bone marrow stromal cell differentiation into endothelial cells via notch signaling pathway. Am J Physiol Cell Physiol 296: C535-C543, 2009.
13. Zacharek A, Chen J, Cui X, Yang Y and Chopp M: Simvastatin increases notch signaling activity and promotes arteriogenesis after stroke. Stroke 40: 254-260, 2009.
14. Aster JC, Xu L, Karnell FG, et al: Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by notch1. Mol Cell Biol 20: 7505-7515, 2000.
15. Bresnick EH, Chu J, Christensen HM, Lin B and Norton J: Linking Notch signaling, chromatin remodeling, and T-cell leukemogenesis. J Cell Biochem Suppl 35 (Suppl.): 46-53, 2000.
16. Wael H, Yoshida R, Kudoh S, et al: Notch signaling controls cell proliferation, apoptosis and differentiation in lung carcinoma. Lung Cancer 85: 131-140, 2014.
17. Ramdass B, Maliekal TT, Lakshmi S, et al: Coexpression of Notch1 and NF-B signaling pathway components in human cervical cancer progression. Gynecol Oncol 104: 352-361, 2007.
18. Wang Z, Banerjee S, Li Y, et al: Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-B, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 66: 2778-2784, 2006.
19. Wang J, Fu L, Gu F and Ma Y: Notch1 is involved in migration and invasion of human breast cancer cells. Oncol Rep 26: 1295-1303, 2011.
20. Qi R, An H, Yu Y, et al: Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 63: 8323-8329, 2003.
21. Yu Y, Zhou XD, Liu YK, et al: Platelets promote the adhesion of human hepatoma cells with a highly metastatic potential to extracellular matrix protein: involvement of platelet P-selectin and GP IIb-IIIa. J Cancer Res Clin Oncol 128: 283-287, 2002.
22. Yu H, Zhao X, Huang S, et al: Blocking Notch1 signaling by RNA interference can induce growth inhibition in HeLa cells. Int J Gynecol Cancer 17: 511-516, 2007.
23. Singh L, Pushker N, Saini N, et al: Expression of pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins in human retinoblastoma. Clin Experiment Ophthalmol: Jul 31, 2014 (Epud ahead of print).
24. Gao J, Yan Q, Liu S and Yang X: Knockdown of EpCAM enhaces the chemosensitivity of breast cancer cells to 5-fluorouracil by downregulating the antiapoptotic factor Bcl-2. PLoS One 9: e102590, 2014.
25. Ekström L, Johansson M, Monostory K, et al: Simvastatin inhibits the core promoter of the TXNRD1 gene and lowers cellular TrxR activity in HepG2 cells. Biochem Biophys Res Commun 430: 90-94, 2013.
26. Liao JK: Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110: 285-288, 2002.
27. Shimada T, Takeshita Y, Murohara T, et al: Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation 110: 1148-1155, 2004.
28. Seeger H, Wallwiener D and Mueck A: Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes 111: 47-48, 2003.
29. Mandal CC, Ghosh-Choudhury N, Yoneda T, Choudhury GG and Ghosh-Choudhury N: Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem 286: 11314-11327, 2011.
30. Hwang KE, Na KS, Park DS, et al: Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs 29: 945-952, 2011.
31. Hussain B, Saleh GM, Sivaprasad S and Hammond CJ: Changing from Snellen to LogMAR: debate or delay? Clin Experimental Ophthalmol 34: 6-8, 2006.
32. Sriuranpong V, Borges MW, Ravi RK, et al: Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 61: 3200-3205, 2001.
33. Shou J, Ross S, Koeppen H, de Sauvage FJ and Gao WQ: Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res 61: 7291-7297, 2001.
34. Talora C, Sgroi DC, Crum CP and Dotto GP: Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev 16: 2252-2263, 2002.
35. Nicolas M, Wolfer A, Raj K, et al: Notch1 functions as a tumor suppressor in mouse skin. Nature Genet 33: 416-421, 2003.
36. Ahn S, Hyeon J and Park CK: Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 12: 286-294, 2013.
37. Zhou L, Zhang N, Song W, et al: The significance of Notch1 compared with Notch3 in high metastasis and poor overall survival in hepatocellular carcinoma. PLoS One 8: e57482, 2013.
38. Masaki T, Shiratori Y, Rengifo W, et al: Cyclins and cyclin-dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 37: 534-543, 2003.
39. Basu A and Haldar S: The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod 4: 1099-1109, 1998.
40. Somanath P, Vijai J, Kichina J, Byzova T and Kandel E: The role of PAK-1 in activation of MAP kinase cascade and oncogenic transformation by Akt. Oncogene 28: 2365-2369, 2009.
41. Goc A, Al-Husein B, Kochuparambil ST, et al: PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer. Int J Oncol 38: 267-277, 2011.
42. Crowell JA, Steele VE and Fay JR: Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 6: 2139-2148, 2007.
43. Davies MA: Regulation, role, and targeting of Akt in cancer. J Clin Oncol 29: 4715-4717, 2011.
44. Amaravadi R and Thompson CB: The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115: 2618-2624, 2005.
45. Vaira V, Lee CW, Goel HL, et al: Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 26: 2678-2684, 2006.